Merck Global Health Innovation Fund

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

– Transcarent, a new and different consumer-directed health and care experience for employees of self-insured employers and their families, announced a $58m Series B investment led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, and Threshold Ventures along with existing investors Alta Partners and Jove Equity Partners.
– This round brings Transcarent’s total funding to $98m and will allow the company to respond to the demand for rapid expansion of its innovative risk-based offering for self-insured employers.